Akorn, Inc. (AKRN) Signs Letter Of Intent With Fidia Farmaceutici, S.p.A. To Develop Four ANDA Drug Products For Commercialization
10/19/2005 5:13:21 PM
BUFFALO GROVE, Ill.--(BUSINESS WIRE)--Oct. 13, 2005--Akorn, Inc. (AMEX:AKN) today announced that it has signed a Letter of Intent with Fidia Farmaceutici S.p.A., a privately-held pharmaceutical company located in Abano Terme (Padova), Italy, to develop four ANDA drug products. The Letter of Intent anticipates executing a Definitive Agreement within ninety days upon Terms and Conditions agreeable to both Akorn and Fidia.
comments powered by